John Wagener, MD
Interventional Cardiology · Sioux Falls, SDNPI 1972879161
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.1% of it on its own, with 16 other manufacturers making up the rest.
Across 243 payments — averaging $147.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- Edwards Lifesciences$4K
- Abbott$4K
- Boston Scientific$387
- Opsens Inc.$373
- Shockwave Medical, Inc$369
- plus $586 from 11 others
Across 17 payments — averaging $5105.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$87K
What the payments were for
- Consulting fees$20,98458%
- Travel & lodging$6,01617%
- Food & beverage$8,94125%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 80 | $26,276 |
| Edwards Lifesciences | 63 | $4,014 |
| Abbott | 40 | $3,935 |
| Boston Scientific | 8 | $387 |
| Opsens Inc. | 5 | $373 |
| Shockwave Medical, Inc | 23 | $369 |
| Abiomed | 8 | $214 |
| Penumbra, Inc. | 2 | $130 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $62 |
| W. L. Gore & Associates, Inc. | 3 | $53 |
| Cardiac Dimensions, Inc. | 1 | $26 |
| Terumo Medical Corporation | 1 | $23 |
| Biosense Webster, Inc. | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Corindus Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$23,227
- MitraClip$1,633
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,300
- CoreValve Evolut$1,234
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$452
- SAPIEN 3 Ultra RESILIA$286
- EVOQUE$275
- OptoWire$157
- OptoMonitor$157
- NAVITOR$153
- Watchman$150
- PASCAL$126
- Indigo$110
- Xience Sierra Coronary Stent System$105
How this compares
Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 20 | $437,275 |
| EliquisApixaban | 106 | $82,876 |
| EntrestoSacubitril/Valsartan | 43 | $30,937 |
| JardianceEmpagliflozin | 61 | $29,509 |
| Repatha SyringeEvolocumab | 31 | $11,191 |
| FarxigaDapagliflozin Propanediol | 11 | $6,168 |
| Metoprolol Succinate | 227 | $2,738 |
| Enoxaparin Sodium | 21 | $2,215 |
| Atorvastatin Calcium | 215 | $1,724 |
| Carvedilol | 271 | $1,038 |
| ClopidogrelClopidogrel Bisulfate | 139 | $914 |
| Torsemide | 27 | $883 |
| Ranolazine ErRanolazine | 17 | $717 |
| Potassium Chloride | 32 | $620 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 55 | $615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $15 | $520,151126 claims |
| AstraZenecaFarxiga | $13 | $6,16811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Sioux Falls
- Sean HalliganSioux Falls$12K
- Tomasz StysSioux Falls$9K
- Adam StysSioux Falls$7K
- Marian PetraskoSioux Falls$4K
- Thomas WaterburySioux Falls$1K
- Raymond AllenSioux Falls$885
- Jeremy ScottSioux Falls$344
- Tarek MahrousSioux Falls$178
- Joseph TumaRapid City$61K
- Thomas WilsonRapid City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.